Tirzepatide vs Liraglutide: What the Research Compares

Tirzepatide and liraglutide are often discussed in the same breath because both are injectable prescription medicines that act on incretin pathways and both have been studied for glucose control and body weight. They are not, however, the same class of drug, and the published evidence for each was generated in separate trial programmes. This page describes what the literature reports for each, where comparisons have been made, and where they have not. It does not recommend either medicine, and it contains no dosing information. This page is for educational purposes only and is not medical advice; consult a licensed physician or other qualified prescriber about any medication decision.

The short answer: no dedicated head-to-head trial in this literature set

Within the published work summarised here, no randomised controlled trial was designed specifically to pit tirzepatide directly against liraglutide. What exists instead are three indirect lines of evidence: narrative and systematic reviews that describe each agent's trial programme separately, network meta-analyses that place multiple incretin drugs into one statistical framework, and real-world analyses of prescribing and outcomes. A 2025 review of real-world evidence examined utilisation, comparative effectiveness and adverse effects across newer GLP-1 receptor agonist-based weight-loss therapies rather than a single agent in isolation (PMID 40196933). Indirect comparison is weaker evidence than a head-to-head trial, because patient populations, trial durations and endpoints differ between studies.

Two molecules, two classes

Liraglutide

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a single-receptor incretin mimetic. A 2023 JAMA review of obesity management in adults placed liraglutide among the pharmacological options described for adults with obesity alongside lifestyle and surgical approaches (PMID 38015216). It was among the earlier incretin-based agents to enter clinical use, so its literature spans a longer period than that of the co-agonists.

Tirzepatide

Tirzepatide acts at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor, which is why reviews describe it as a dual agonist or co-agonist rather than a GLP-1 receptor agonist. A 2025 review of the mechanisms involved in obesity treatment discussed GLP-1-based medications together with co-agonist approaches that recruit more than one incretin receptor (PMID 40466247). A 2024 JAMA review of medications for obesity likewise grouped the newer incretin-based agents within the broader pharmacotherapy landscape (PMID 39037780).

Mechanism: what reviews describe

Reviews of GLP-1-based pharmacotherapy described appetite regulation, central signalling and effects on gastric emptying as contributors to the weight changes observed with this drug family (PMID 40466247). The same 2025 mechanistic review covered how co-agonist designs differ from single-receptor agonists in the pathways they engage (PMID 40466247). Researchers writing on gastrointestinal effects noted that slowed gastric motility is mechanistically linked to both the therapeutic and the tolerability profile of GLP-1 receptor agonists (PMID 39096914).

Regulatory status, described factually

Both tirzepatide and liraglutide are prescription medicines dispensed under a clinician's supervision; neither is something a consumer can legitimately self-select. Reviews of obesity pharmacotherapy discussed approved medications for chronic weight management and for type 2 diabetes as distinct regulatory categories, with separate product labelling for each indication (PMID 39037780). Which product, which indication and which patient a given medicine is appropriate for are determinations made by a prescribing clinician against the current approved labelling in the relevant country — not questions this page answers.

What the published studies measured for each

Weight outcomes

A 2025 systematic review in Annals of Internal Medicine assessed randomised controlled trials of GLP-1 receptor agonists for weight loss among adults without diabetes and summarised both efficacy and safety outcomes across that trial set (PMID 39761578). Because the agents in such reviews were tested in separate trials with different comparators, the reviewers' pooled estimates describe the class and its members rather than establishing a direct ranking between any two named drugs (PMID 39761578). The 2024 JAMA review of medications for obesity similarly placed the incretin agents within the wider set of approved anti-obesity drugs (PMID 39037780).

Body composition

A 2025 systematic review and network meta-analysis in Metabolism examined the effect of GLP-1 receptor agonists and co-agonists on body composition, bringing single-receptor agonists and dual agonists into one comparison network (PMID 39719170). That analysis is the closest thing in this citation set to a structured comparison between the two drug types, and the researchers reported on fat mass and lean mass changes rather than weight alone (PMID 39719170). A 2024 Diabetes Care commentary asked whether resistance exercise could optimise body-composition changes during incretin-based weight-loss pharmacotherapy, reflecting ongoing interest in lean-mass preservation across the whole drug family (PMID 38687506).

Real-world use

The 2025 real-world evidence review covered how newer GLP-1 receptor agonist-based weight-loss therapies were actually used in practice, along with comparative effectiveness signals and adverse effects observed outside trial conditions (PMID 40196933). Real-world datasets can compare agents that were never tested against each other, but researchers have long cautioned that confounding by indication and by patient characteristics limits what such comparisons prove (PMID 40196933).

Adverse Events: What Studies Report

The adverse-event literature for these medicines is largely described at class level rather than drug by drug. A 2024 Lancet Gastroenterology & Hepatology review examined the gastrointestinal effects of GLP-1 receptor agonists, covering mechanisms, clinical management and research gaps (PMID 39096914). The 2025 Annals systematic review of randomised trials in adults without diabetes reported on safety outcomes alongside efficacy in that trial set (PMID 39761578), and the real-world review described adverse effects recorded in routine-care data (PMID 40196933).

A 2026 narrative review in Clinical Obesity examined micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy, a topic the authors framed as a consequence of reduced intake during treatment (PMID 41549912). None of these publications replaces a prescriber's assessment of an individual's risk profile.

What happens after stopping

A 2025 systematic review and meta-analysis in Obesity Reviews examined discontinuation of GLP-1 receptor agonists and subsequent changes in body habitus, pooling studies that followed participants after treatment ended (PMID 40186344). This question has been studied as a class-level issue rather than as a tirzepatide-versus-liraglutide comparison (PMID 40186344).

Populations the literature treats separately

• Pregnancy: a 2025 review in the American Journal of Obstetrics and Gynecology surveyed GLP-1 receptor agonist use in pregnancy and the limitations of the available data (PMID 39181497).
• Older adults: a 2024 Drugs & Aging review addressed pharmacological treatment of obesity in older adults, where comorbidity and body-composition concerns shape the discussion (PMID 39514148).
• Adults without diabetes: the 2025 Annals review restricted itself to randomised trials in this group (PMID 39761578).

What this comparison does not settle

Because no trial in this set randomised participants to tirzepatide or liraglutide and followed them under identical conditions, the literature cannot say which medicine performs better for a given individual. Indirect evidence from network meta-analysis (PMID 39719170) and real-world analysis (PMID 40196933) narrows the uncertainty but does not remove it. Reviews of obesity management also emphasise that pharmacotherapy sits within a broader framework of behavioural, nutritional and sometimes surgical care (PMID 38015216).

Reasonable questions for a prescribing clinician

1. Which approved indication, if any, applies to a given person's medical situation?
2. How do existing conditions and other prescriptions affect suitability?
3. What monitoring is appropriate, including for gastrointestinal tolerability described in the literature (PMID 39096914)?
4. What is the plan for nutrition and for muscle-mass considerations raised in body-composition research (PMID 38687506)?
5. What does the evidence on discontinuation imply for long-term planning (PMID 40186344)?

Related reading: tirzepatide and liraglutide.

References

• Obesity Management in Adults: A Review (JAMA, 2023)
• GLP-1-based medications: Mechanisms involved in obesity treatment (Medicina Clinica, 2025)
• Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis (Metabolism, 2025)
• Medications for Obesity: A Review (JAMA, 2024)
• Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? (Diabetes Care, 2024)
• Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies (Diabetes, Obesity & Metabolism, 2025)
• Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials (Annals of Internal Medicine, 2025)
• Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review (Clinical Obesity, 2026)
• Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis (Obesity Reviews, 2025)
• Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions (Lancet Gastroenterology & Hepatology, 2024)
• Glucagon-like peptide-1 receptor agonist use in pregnancy: a review (American Journal of Obstetrics and Gynecology, 2025)
• Pharmacological Treatment of Obesity in Older Adults (Drugs & Aging, 2024)